Epoetin alfa biosimilar - Wockhardt

Drug Profile

Epoetin alfa biosimilar - Wockhardt

Alternative Names: Recombinant human erythropoietin biosimilar - Wockhardt; Wepox

Latest Information Update: 27 Aug 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wockhardt
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 01 Jan 2011 Launched for Anaemia in Philippines (IV)
  • 01 Jan 2011 Launched for Anaemia in Ukraine (IV)
  • 01 Sep 2002 Launched for Anaemia in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top